Image credit: LIBD

BrainSEQ™ Consortium

Image credit: LIBD

BrainSEQ™ Consortium

The Lieber Institute and pharmaceutical companies AstraZeneca, Astellas, Eli Lilly and Company, Lundbeck, Johnson & Johnson, Pfizer Inc. and Roche are participating in an early-stage research consortium BrainSEQ™, with the goal of expanding knowledge around the genetic contribution to brain disorders in the hope of identifying potential new treatment options.

  • Utilizing LIBD’s unprecedented brain tissue repository to generate and analyze genomic data related to neuropsychiatric disorders.
  • Making data freely available to scientists worldwide.

As part of the BrainSeq Consortium I have analyzed parts of Phase I and II data, either for the publications describing those phases or for re-analyses of the same data.

Avatar
Leonardo Collado-Torres
Staff Scientist II

Brain genomics #rstats coder working w/ @andrewejaffe @LieberInstitute. @lcgunam @jhubiostat @jtleek alumni. @LIBDrstats @CDSBMexico co-founder.

Publications

Talks

Update on BrainSeq Phase II and recount-brain for the LIBD 2019 staff seminar series

Overview of some of our work at LIBD on the field of interactive displays